SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target proteins in cells by Zucchelli, Silvia et al.
ORIGINAL RESEARCH
published: 13 May 2015
doi: 10.3389/fncel.2015.00174
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 May 2015 | Volume 9 | Article 174
Edited by:
Rosanna Parlato,
Ulm University, Germany
Reviewed by:
Mohammadreza Hajjari,
Shahid Chamran University of Ahvaz,
Iran
Rohit Mathur,
M.D. Anderson Cancer Center, USA
*Correspondence:
Stefano Gustincich,
Scuola Internazionale Superiore di
Studi Avanzati, Sector of
Neurobiology, Via Bonomea 265,
34136 Trieste, Italy
gustinci@sissa.it
†
These authors have contributed
equally to this work.
Received: 10 December 2014
Accepted: 20 April 2015
Published: 13 May 2015
Citation:
Zucchelli S, Fasolo F, Russo R, Cimatti
L, Patrucco L, Takahashi H, Jones
MH, Santoro C, Sblattero D, Cotella
D, Persichetti F, Carninci P and
Gustincich S (2015) SINEUPs are
modular antisense long non-coding
RNAs that increase synthesis of target
proteins in cells.
Front. Cell. Neurosci. 9:174.
doi: 10.3389/fncel.2015.00174
SINEUPs are modular antisense long
non-coding RNAs that increase
synthesis of target proteins in cells
Silvia Zucchelli 1, 2 †, Francesca Fasolo 1†, Roberta Russo 1, Laura Cimatti 1,
Laura Patrucco 2, Hazuki Takahashi 3, Michael H. Jones 4, Claudio Santoro 2,
Daniele Sblattero 2, Diego Cotella 2, Francesca Persichetti 2, Piero Carninci 3 and
Stefano Gustincich 1*
1 Scuola Internazionale Superiore di Studi Avanzati, Area of Neuroscience, Trieste, Italy, 2Dipartimento di Scienze della Salute,
Universita’ del Piemonte Orientale, Novara, Italy, 3Division of Genomic Technologies, RIKEN Center for Life Science
Technologies, Yokohama, Japan, 4Cell Guidance Systems, Cambridge, UK
Despite recent efforts in discovering novel long non-coding RNAs (lncRNAs) and
unveiling their functions in a wide range of biological processes their applications as
biotechnological or therapeutic tools are still at their infancy. We have recently shown
that AS Uchl1, a natural lncRNA antisense to the Parkinson’s disease-associated
gene Ubiquitin carboxyl-terminal esterase L1 (Uchl1), is able to increase UchL1 protein
synthesis at post-transcriptional level. Its activity requires two RNA elements: an
embedded inverted SINEB2 sequence to increase translation and the overlapping region
to target its sense mRNA. This functional organization is shared with several mouse
lncRNAs antisense to protein coding genes. The potential use of AS Uchl1-derived
lncRNAs as enhancers of target mRNA translation remains unexplored. Here we define
AS Uchl1 as the representative member of a new functional class of natural and synthetic
antisense lncRNAs that activate translation. We named this class of RNAs SINEUPs
for their requirement of the inverted SINEB2 sequence to UP-regulate translation in
a gene-specific manner. The overlapping region is indicated as the Binding Doman
(BD) while the embedded inverted SINEB2 element is the Effector Domain (ED). By
swapping BD, synthetic SINEUPs are designed targeting mRNAs of interest. SINEUPs
function in an array of cell lines and can be efficiently directed toward N-terminally tagged
proteins. Their biological activity is retained in a miniaturized version within the range of
small RNAs length. Its modular structure was exploited to successfully design synthetic
SINEUPs targeting endogenous Parkinson’s disease-associated DJ-1 and proved to be
active in different neuronal cell lines. In summary, SINEUPs represent the first scalable
tool to increase synthesis of proteins of interest. We propose SINEUPs as reagents
for molecular biology experiments, in protein manufacturing as well as in therapy of
haploinsufficiencies.
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Introduction
Large genomic projects such as ENCODE (Djebali et al., 2012)
and FANTOM (Forrest et al., 2014) have shown that the majority
of the mammalian genome is transcribed, thus generating
a previously underestimated complexity in gene regulatory
networks. Protein encoding genes present a large repertory
of alternative Transcription Start Sites (TSSs) that may drive
transcription in a cell type-specific manner (Valen et al., 2009).
Different 5′UTRs may contain information for mRNA sorting
to neuronal compartments as well as for stimulus-dependent
translation. Furthermore, in addition to 25000 genes encoding
for proteins, at least an equal number of long non-coding RNA
(lncRNA) genes have been identified so far. These generate>200
base pairs long transcripts that do not encode for proteins.
About one third of annotated lncRNAs overlaps with protein-
coding genes (Derrien et al., 2012). Many of these are transcribed
from the opposite strand forming sense/antisense (S/AS) pairs
(Katayama et al., 2005; Derrien et al., 2012).
The nervous system appears as a privileged site for lncRNA
expression, as the vast majority of these transcripts is brain-
enriched and regulates neuronal development and functions
(Qureshi and Mehler, 2012). Furthermore, a complex network
of natural S/AS pairs may participate in brain development
and homeostasis in physiological conditions. Interestingly, an
increasing number of lncRNAs are associated with brain
dysfunction and extensive AS transcription has been measured
in loci associated to hereditary neurodegenerative diseases
(Zucchelli et al., submitted).
Manipulating RNA expression in vivo has been proposed as
new strategy for molecular therapy. Special attention has been
devoted to small antisense oligonucleotides (ASOs) and siRNAs
as tools to decrease gene expression of pathological target genes
such as, for example, mutant huntingtin in Huntington’s disease
(Kordasiewicz et al., 2012; Yu et al., 2012).
An equally challenging large group of diseases would
strongly benefit from the discovery of RNAs that can increase
protein levels of genes for which low expression is pathogenic.
Several hereditary intellectual and cognitive disabilities are
haploinsufficiencies where only a single functional copy of a gene
is unable to produce sufficient protein tomaintain a physiological
condition (Van Bokhoven, 2011). Therefore an RNA-based drug
that can restore physiological amounts of the target protein can
in principle be curative. Unfortunately, no molecules that can
increase protein levels of a specific mRNA type in vivo have been
found to date.
In search for AS transcripts that may regulate the expression
of Parkinson’s disease (PD)-associated genes, we recently
discovered AS Uchl1, a natural lncRNA antisense to Ubiquitin
carboxyl-terminal esterase L1 (Uchl1/PARK5) (Carrieri et al.,
2012). AS Uchl1 is a nuclear-enriched transcript, that is expressed
in dopaminergic neurons in the Substantia Nigra, the target
Abbreviations: lncRNA, long non-coding RNA; AS, antisense; SINE, short
interspersed nuclear element; invSINEB2, inverted SINE of B2 subfamily; PD,
Parkinson’s disease; TRAF6, tumor necrosis factor receptor associated factor
6; TTRAP/TDP2, TRAF and TNF receptor associated protein/tyrosyl-DNA
phosphodiesterase 2; Hba, hemoglobin alpha chain.
of PD neurodegeneration, and is down-regulated upon PD-
mimicking intoxication in vitro and in vivo (Carrieri et al.,
2015). AS Uchl1 activity increases UchL1 protein synthesis at
the post-transcriptional level. Upon stressful insults, AS Uchl1
shuttles from the nucleus to the cytoplasm, where it induces
Uchl1 mRNA association to heavy polysomes to increase its
translation (Carrieri et al., 2012). AS Uchl1 activity depends
on two functional domains: the overlapping region that defines
target specificity and the inverted SINE element of B2 subclass
(invSINEB2) that confers protein synthesis activation. This
functional organization is shared with other lncRNAs part of
S/AS pairs in the mouse genome. Finally, by substituting the
overlapping region with a sequence antisense to the Green
Fluorescent Protein (GFP) mRNA, this synthetic RNA was able
to increase GFP protein synthesis with a post-transcriptional
mechanism (Carrieri et al., 2012).
The potential scalability of AS Uchl1-derived synthetic
lncRNAs to a platform of mRNA-specific translation enhancers
remained to be addressed.
Here we propose that AS Uchl1 is the representative member
of a new functional class of natural and synthetic RNAs that
increase protein synthesis. We name these RNAs as SINEUPs
for their activity requires an invSINEB2 element (SINE) to UP-
regulate translation of partially overlapping sense mRNAs. The
overlapping region is indicated as the Binding Doman (BD) while
the embedded inverted SINEB2 element is the Effector Domain
(ED). By swapping BD, synthetic SINEUPs are designed targeting
mRNAs of interest.
This work shows that synthetic SINEUPs are a versatile tool
to increase synthesis of target proteins of interest paving the
way for future applications of SINEUPs as molecular biology
reagents and for manufacturing of recombinant proteins. Most
importantly, SINEUPs may be directed to selected mRNA species
in vivo representing a new type of RNA-based drug for molecular
therapy.
Materials and Methods
Constructs
Plasmids expressing target proteins were previously described.
In particular, for this study we used pEGFP-C2 (Carrieri et al.,
2012), pcDNA3-2XFLAG-DJ-1 (Herrera et al., 2007; Zucchelli
et al., 2009), pcDNA3-2XFLAG-TTRAP (Zucchelli et al., 2009;
Vilotti et al., 2012), pcDNA3-2XFLAG-Hba (Biagioli et al.,
2009) (Codrich et al., manuscript in preparation) and pcDNA3-
2XFLAG-TRAF6 (Zucchelli et al., 2010, 2011).
Target specific SINEUPs were constructed using pcDNA3-
15′-ASUchl1 as backbone (Carrieri et al., 2012). SINEUP-
backbone lacks the region of overlap (BD) to Uchl1 and retains
AS Uchl1 ED with inverted SINEB2, Alu sequence and 3′
tail. SINEUP target-specific BDs were designed, in antisense
orientation, around the ATG of protein-coding sequence with
a−40/+32 anatomy.
SINEUP targeting EGFP (AS-GFP, here named SINEUP-GFP)
has been described in Carrieri et al. (2012). SINEUP targeting
FLAG-tagged proteins (SINEUP-FLAG) was cloned with the
following primers (5′ to 3′ orientation):
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FWD AS 2xFLAG:
ATATCTCGAGAATTCCTTGTCATCGTCGTCCTTGTAGT
CCATCAATTCCAGCACACTGGCGGCCGT
REV AS 2xFLAG:
GAGAGATATCCTCGGATCCACTAGTAACGGCCGCCAG
TGTGCTGGAATTGATGGACTACAAGGACG
Primers were annealed, elongated by PCR, digested and
ligated into XhoI-EcoRV sites of SINEUP-backbone.
Short SINEUP targeting GFP (miniSINEUP-GFP) was
generated combining BD of SINEUP-GFP and ED of AS Uchl1.
Briefly, inverted SINEB2 was PCR amplified and cloned into
EcoRI and HindIII sites of pcDNA3.1(-). SINEUP-GFP BD was
subsequently added to the inverted SINEB2-containing plasmid
at XhoI and EcoRI sites to obtain miniSINEUP-GFP. The
following primers were used:
FWD EcoRI InvSINEB2: TATAGAATTCCAGTGCTAGA
GGAGG
REV HindIII InvSINEB2: GAGAAAGCTTAAGAGACTG
GAGC
FWD ApaI all O/L: TATAGGGCCCTCTAGACTCGAG
REV EcoRI O/L GFP20: GAGAGAATTCCAGCACAG
TGGCGGCCGC
SINEUPs targeting DJ-1 were generated by annealing and
PCR-based method (−40/+32) or with annealing and ligation of
phosphorylated oligonucleotides (−40/+4), using the following
primers:
SINEUP-DJ-1 (−40/+32) FWD:
ATATCTCGAGGCCAGGATGACCAGAGCTCTTTTGG
AAGCCATTTTTATGTTATATGTTT
SINEUP-DJ-1 (−40/+32) REV:
GAGAGATATCTTTCAGCCTGGTGTGGGGCTTGT
AAACATATAACATAAAAATGGCTT
SINEUP-DJ-1 (−40/+4) FWD:
TCGAGCCATTTTTATGTTATATGTTTACAAGCCCCACA
CCAGGCTGAAA
SINEUP-DJ-1 (−40/+4) REV:
TTTCAGCCTGGTGTGGGGCTTGTAAACATATAACAT
AAAAATGGC
All constructs were verified by sequencing.
Cell Lines and Transfection
HEK 293T/17 cells were obtained from ATCC (Cat. No. ATCC-
CRL-11268 293T/17) and maintained in culture with Dulbecco’s
Modified Eagle Medium (GIBCO) supplemented with 10%
FBS (SIGMA) and 1% antibiotics (penicillin/streptomycin), as
suggested by the vendor. HepG2 cells were kindly provided
by Professor Collavin L. from the University of Trieste, Italy
(Lunardi et al., 2009). HepG2 and SK-N-SH were cultured
in Eagle’s minimal essential medium (SIGMA) supplemented
with 10% FBS, 1% antibiotics, 1% GlutaMAX and 1% non-
essential aminoacids. HeLa cells were grown with DMEM
supplemented with 10% FBS and 1% antibiotics as previously
described (Angelini et al., 2007). SH-SY5Y cells were maintained
in culture as previously described (Zucchelli et al., 2009).
BE(2)M17 were grown in 1:1 MEM-Glutamax (GIBCO)/F12
(GIBCO) supplemented with 10% FBS, 1% antibiotics, and 1%
non-essential aminoacids.
When required, HEK 293T/17 cells were treated with
rapamycin (SIGMA) at 1µM for 1 h or at 100 nM for 16 h. DNA
damage was induced by doxorubicin (SIGMA), at 1µM for 1 h or
500 nM for 16 h.
HEK 293T/17 cells were transfected with Fugene HD
(Roche) and Lipofectamine 2000 (Life Technologies), following
manufacture’s instruction. HepG2, HeLa, SH-SY5Y, BE(2)M17
and SK-N-SH cells were transfected with Lipofectamine 2000. All
cells were transfected with a 1:6 ratio between sense and SINEUP
encoding plasmids, maintaining the conditions described for
S/AS Uchl1 (Carrieri et al., 2012). In detail, cells were plated in
6-well plates the day before transfection at 60% (for Fugene HD
protocol) or 80–90% (for Lipofectamine protocol) confluency.
For transfection with Fugene 0.3µg pEGFP and 1.8µg SINEUP
plasmid were used; for Lipofectamine 2000 0.6µg pEGFP and
3.4µg SINEUP. Cells were collected at 24 h (HeLa cells) or 48 h
(HEK 293T/17 and HepG2 cells) after transfection and split in
two samples for RNA extraction and Western Blot analysis.
For SINEUPs targeting endogenous mRNAs, SINEUP-
encoding plasmid was transfected at the highest dose (4µg)
following manufacture’s instructions.
Data of RNA and protein levels were obtained from the same
transfection in each replica.
Western Blot
For Western blot analysis, cell pellets were directly resuspended
in Laemli sample buffer, briefly sonicated, boiled and loaded on
poly-acrilamide gels.
Primary antibodies used in this study include anti-GFP rabbit
polyclonal antibody (Life Techologies, Cat. No. A6445), used
1:1000, anti-FLAG M2 (SIGMA, Cat. No. 3165), 1:1000, anti-β-
actin (SIGMA), 1:5000, and anti-TRAF6 (Abnova), used 1:500.
To detect endogenous DJ-1 protein an antibody produced in
our laboratory was used (Zucchelli et al., 2009; Foti et al.,
2010). For the detection, anti-mouse-HRP or anti-rabbit-HRP
(Dako) in combination with ECL (GE Healthcare) was used.
Image detection was performed with Alliance LD2-77WL system
(Uvitec, Cambridge). Image quantificationwas done using Adobe
Photoshop CS5.
RNA Isolation, Reverse Transcription and
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells using RNeasy Mini Kit
(QIAGEN) following manufacturer’s instructions. RNA was
treated with on-columnDNase I (QIAGEN) followed by a second
DNase I digestion in solution (Ambion). Two rounds of DNase
digestion were required to avoid plasmid DNA contamination in
this experimental setting. Single strand cDNAwas prepared from
1µg of purified RNA using the iSCRIPT™ cDNA Synthesis Kit
(Bio-Rad) according to manufacturer’s instructions. qRT-PCR
reaction was performed on diluted cDNA (1:20) using SYBR-
Green PCR Master Mix (Applied Biosystem) and an iCycler
IQ Real time PCR System (Bio-Rad). Relative expression was
calculated with the11Ct method (Schmittgen and Livak, 2008).
Oligonucleotide sequences of primers used in this study for GFP
and GAPDH (Carrieri et al., 2012), DJ-1 (Foti et al., 2010),
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TTRAP (Zucchelli et al., 2009), TRAF6 (Zucchelli et al., 2010)
and Hba (Biagioli et al., 2009) were previously described.
SINEUP-GFP, SINEUP-FLAG and SINEUP-DJ-1 were
detected with primers designed on the 3′ end of AS-Uchl1
(mAS Uchl1 FWD and REV, Primers 3′) (Carrieri et al., 2012).
MiniSINEUP-GFP was quantified using the following primers:
pTSinvB2 FWD-RT (CAGTGCTAGAGGAGGTCAGAAGA)
and pTSinvB2 REV-RT (GGAGCTAAAGAGATGGCTCAG
CACTT).
Cellular Fractionation
For fractionation experiments, GFP/SINEUP-GFP were
transfected in 10 cm plates at 1:6 ratio using Lipofectamine 2000.
Nucleo cytoplasmic fractionation was performed as previously
described (Wang et al., 2006). Nucleus and cytoplasmic RNAs
were extracted using Trizol reagent (Invitrogen) following
manufacturer’s instruction. RNA was eluted and treated with
DNase I. The purity of the cytoplasmic fractions was confirmed
by qRT-PCR on pre-ribosomal RNA using the following primers
(Murayama et al., 2008):
FWD 5′-GAACGGTGGTGTGTCGTTC-3′
REV 5′-GCGTCTCGTCTCGTCTCACT-3′
Statistical Analysis
All data are expressed as mean ± standard deviation on n ≥ 3
replicas. Statistical analysis was performed using Excel software.
Statistically significant differences were assessed by Student’s t-
test. Differences with p < 0.05 were considered significant.
Results
SINEUPs: Definition and Design
As shown in Carrieri et al. (2012), ASUchl1 stimulates translation
of partially overlapping sense protein-coding mRNAs with no
effects on RNA levels.
Here we propose AS Uchl1 as the representative member of a
new functional class of natural and synthetic antisense lncRNAs
that activate translation. We named these lncRNAs as SINEUPs
since they take advantage of an embedded invSINEB2 element to
UP-regulate translation. Therefore SINEUPs can be considered
the first example of gene-specific inducers of protein synthesis.
SINEUPs display a modular architecture (Figure 1A). In
the 5′ region, SINEUPs contain the sequence that overlaps, in
antisense orientation, to the sense protein-coding mRNA. We
named this sequence as SINEUP’s Binding Domain (BD) since it
provides target selection and SINEUP specificity by RNA-RNA
base pairing. In AS Uchl1, BD is 73 base pair long, centered
across the ATG with a −40/+32 configuration, spanning part of
Uchl1 5′UTR and a portion of its CDS (Carrieri et al., 2012). The
remaining SINEUP sequence presents the embedded invSINEB2
element in the non-overlapping part of the transcript. Since
this region has been proven essential for protein synthesis up-
regulation, we defined it as Effector Domain (ED) (Figure 1A).
FIGURE 1 | Schematic representation of SINEUPs. (A) SINEUP modular
structure. SINEUP binding domain (gray): SINEUP sequence that overlaps, in
antisense orientation, to the sense protein-coding mRNA. SINEUP effector
domain (red): non-overlapping portion of SINEUPs (white), containing the
inverted SINEB2 element (invB2) that confers activation of protein synthesis.
5′ to 3′ orientation of sense and antisense RNA molecules is indicated.
Structural elements of protein-coding mRNA are shown: 5′ untranslated
region (5′UTR, blue), coding sequence (CDS, green) and 3′ untranslated
region (3′UTR, yellow). (B) SINEUP design strategy. Schematic
representation of the cloning strategy to generate target-specific SINEUPs.
An artificial target gene sequence is indicated as example. SINEUP domains
are represented as in A.
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In Carrieri et al., we showed that this modular structure is
shared with several natural lncRNAs component of S/AS pair in
the mouse genome. For AS Uxt we proved it is able to increase
UXT protein synthesis with no effects on Uxt mRNA levels.
Therefore these define the first entries in the list of natural
SINEUPs.
Given their modular structure, target-specific synthetic
SINEUPs can be designed at will by manipulating AS Uchl1
sequence (Figure 1B). In Carrieri et al., we have designed the
first synthetic SINEUP directing its activity to GFP mRNA
by swapping BDs. However, any invSINEB2 sequence from
other natural SINEUPs can in principle sustain activity and be
considered potential ED.
Provided with the exact TSS for the target gene, sequence of
interest is extrapolated centered across the initiating ATG. After
reverse-complementmanipulation, gene-specific BD is generated
by annealing and PCR amplification of specific oligonucleotides.
Target-specific SINEUP is then obtained by cloning specific BDs
upstream to the SINEUP effector domain. For expression in
mammalian cells, SINEUPs are cloned into pcDNA3.1 plasmid.
Vectors for retroviral and lentiviral packaging can also be
efficiently used (data not shown).
SINEUPs Work in vitro in Different Cell Lines
Mammalian cell cultures in vitro are routinely used as model
systems to study the molecular mechanisms of gene functions
as well as cell factories to produce therapeutic proteins.
Considering the flexibility of SINEUP technology and its
potential applications in molecular biology experiments, protein
manufacturing and therapeutics, we investigated the efficacy
and reproducibility of SINEUPs in different cell lines in vitro.
To this purpose we selected hepatocellular carcinoma HepG2
cells, for their use as a model system by large multicenter
consortia, epithelial carcinoma HeLa cells for their wide use in
cell biology and in therapeutic protein production as well as
HEK 293T/17 cells as positive control of SINEUP activity. As a
representative synthetic SINEUP, we took advantage of SINEUP-
GFP to increase GFP protein levels in transient overexpression
experiments.
We estimated SINEUP activity as fold changes in protein
levels encoded by targeted mRNAs in the presence/absence of
SINEUP with mRNA amounts kept constant (p > 0.05).
Similar fold-changes were observed for SINEUP activity with
GFP target at 24 and 48 h after transfection (data not shown).
However timing for optimal activity was cell-line dependent, as
best conditions were found at 24 h in HeLa and 48 h in HEK
293T/17 and HepG2 cells (Figures 2A–C).
In HEK 293T/17 cells we obtained an average 2.4 fold change
(Figure 2A), confirming previously published data (Carrieri
et al., 2012) on an independent batch of cells and on a larger
cohort of transfections. SINEUP activity ranged from aminimum
of 60% induction to a maximum of 400% (Figure 2D). SINEUP
effect in transfected HEK 293T/17 cells was not enhanced upon
stressful stimuli such as rapamycin and DNA-damage inducing
drug doxorubicin (Supplementary Figure 1). HepG2 cells and
HeLa cells proved to support SINEUP activity (Figures 2B,C),
with an average induction of 1.65 and 1.82-fold, respectively.
Minimal values were 20% in HepG2 and 40% in HeLa cells,
and top effect was 250 and 220% (Figure 2D). No statistical
differences could be measured in SINEUP activity between the
three cell lines (p > 0.05), albeit HEK 293T/17 cells tended to be
more effective (Figure 2D).
We observed that SINEUP activity is maintained
independently of the reagent used for transfection. In HEK
293T/17 cells an average of 2.4 fold change could be measured
with Lipofectamine (n = 5 experiments) and 2.3 with Fugene
HD (n = 6 experiments) (data not shown). Under these
experimental conditions, RNA from transfected SINEUP-
GFP was detected in the cytoplasmic fraction although
a prominent accumulation in the nucleus was evident
(Supplementary Figure 2). Interestingly, sense GFP mRNA
was equally distributed between cytoplasmic and nuclear
compartments. Altogether these data indicate that SINEUPs can
be used in vitro in different cell systems to up-regulate proteins
of interest.
SINEUPs can be Designed to Increase
Production of Target Proteins of Interest
The modular structure of SINEUPs predicts that by swapping the
BD with an appropriate sequence it should be possible to redirect
SINEUP activity to target mRNA of interest.
To test the flexibility of BD design, we generated a
SINEUP molecule targeting the commonly used FLAG
tag sequence. FLAG-specific SINEUP would be able to act
at a post-transcriptional level increasing the quantities of
proteins expressed in frame with an N-terminal FLAG tag.
SINEUP targeting FLAG-tagged proteins (SINEUP-FLAG) was
designed to mimic the molecular anatomy of SINEUP-GFP. In
particular, SINEUP-FLAG BD encompasses −40 nucleotides
(in pcDNA3 plasmid backbone) before FLAG-initiating
Met and +32 bases covering the first FLAG tag sequence
(Figure 3A).
We took advantage of a series of protein-coding genes
available in the laboratory to test SINEUP-FLAG activity.
We used human TRAF6 (RefSeq NM_004620) (Zucchelli
et al., 2010, 2011), human TTRAP (RefSeq NM_016614)
(Zucchelli et al., 2009; Vilotti et al., 2012), human DJ-1
(RefSeq NM_001123377) (Herrera et al., 2007; Zucchelli et al.,
2009) and mouse Hba-a1 (RefSeq NM_008218) (Biagioli et al.,
2009) (Codrich et al., manuscript in preparation) cloned in
pcDNA3-2XFLAG. HEK 293T/17 cells were transfected with
plasmids for FLAG-tagged targets in combination with SINEUP-
FLAG (+SINEUP). Cells transfected with an empty vector were
used as control (-SINEUP). SINEUP activity was measured
quantifying protein levels by Western blot and RNA amounts
by qRT-PCR. We found that the quantity of three of four
FLAG-tagged proteins that we tested was modulated by co-
expression of SINEUP-FLAG (Figure 3B). SINEUP effect was
different toward the three targets, ranging from 1.5 to 3.0
fold changes. FLAG-TRAF6 showed the strongest SINEUP-
mediated activation with a protein induction consistently
in the range of 2.6 to 3.0 fold (Figure 3B and data not
shown). No effect on TRAF6 mRNA was present, as expected
(p = 0.46). Interestingly, increased TRAF6 levels could
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FIGURE 2 | SINEUP activity in cell lines. HEK 293T/17 (A), HepG2 (B)
and HeLa (C) cells were transfected with pEGFP-C2 and SINEUP-GFP at 1:6
ratio (+SINEUP). Control cells were transfected with pEGFP-C2 and an
empty control plasmid (-SINEUP). 24 h (HeLa) or 48 h (HEK 293T/17 and
HepG2) after transfection, cells were lysed and processed for protein (top)
and RNA (bottom) levels. Western blot was performed with anti-GFP
antibody. β-actin was used as loading control. Fold-induction was calculated
on Western blot images normalized to β-actin and relative to empty control
samples. Expression of SINEUP-GFP (white bars) and quantity of GFP
mRNA (gray bars) were monitored by qRT-PCR using specific primers. Data
indicate mean ± standard deviation. Data are representative of >3
independent replicas. (D) Graphical representation of SINEUP-mediated GFP
up-regulation in HEK (n = 10), HepG2 (n = 4) and HeLa (n = 5) cells. No
statistical difference was present between the three cell lines (p > 0.05).
be measured when probing lysates with anti-TRAF6 specific
antibody (Supplementary Figure 3).
A 50% up-regulation was measured with FLAG-DJ-1 and
90% with FLAG-Hba. In both cases, sense mRNA in -SINEUP
and +SINEUP transfections was not statistically different (p =
0.36 in FLAG-DJ-1 samples and p = 0.38 in FLAG-Hba).
A modest activation was observed with FLAG-TTRAP where
a 10–20% increase was typically observed by Western blot.
However, this was consistently accompanied by a similar
modulation of TTRAP mRNA levels (Supplementary Figure 4),
thus excluding this effect from SINEUP definition.
In summary synthetic SINEUPs can be designed to commonly
used tag sequences and the same SINEUP can dictate translation
of different tagged proteins of interest.
MiniSINEUPs Containing Exclusively BD and ED
are Active
A major limitation in the use of naked RNA for in vitro
and in vivo applications is the instability and low cellular
permeability of long molecules. Chemical modifications can by-
pass such limits, but with specific constraints in RNA length.
Synthetic SINEUPs derived from natural AS Uchl1 are about
1200 nucleotides (nt) long with BD of 72 base pairs, ED of 170
base pairs in addition to intervening sequences, a partial Alu
element (73 base pairs) and a 3′ tail. This length is suitable for
delivery systems such as viral vectors, but incompatible with the
use of SINEUPs as naked RNA therapeutic molecules. Therefore,
we aimed at synthesizing the shortest functional SINEUP that
retains its translation enhancement activity. MiniSINEUP-GFP
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FIGURE 3 | Examples of target-specific SINEUPs. (A) Scheme of
FLAG tag-specific SINEUP. SINEUP-FLAG was designed to target the
−40/+32 region around the ATG of 2XFLAG expression plasmid
(pcDNA3-2XFLAG). (B) Activity of SINEUP-FLAG was tested in HEK
293T/17 cells transfected with pcDNA3-2XFLAG-TRAF6, DJ-1 and Hba,
as indicated. Protein (top) and RNA (bottom) levels were analyzed by
Western blot with anti-FLAG antibody and by qRT-PCR with SINEUP
(white) and target-specific (gray) primers, respectively. SINEUP activity
was calculated as increase in protein levels relative to empty control
samples (fold changes are shown). In all conditions, sense RNA
quantities were stable (p > 0.05). Data indicate mean ± standard
deviation and are representative of three independent experiments.
was obtained combining SINEUP-GFP BD and ED from AS
Uchl1 (Figure 4A) giving rise to a≈250 nt long transcript. When
transfected in HEK 293T/17 cells miniSINEUP-GFP promoted
a 2.5 fold increase in GFP protein levels with unaffected mRNA
quantities (p = 0.11) (Figure 4B). Interestingly, the activity of
miniSINEUP was comparable to that obtained with SINEUP-
GFP (1.6 fold in this experiment, 2.4 average increase in HEK
293T/17 cells, Figure 2D). Under these conditions, we observed
a 10-fold excess of miniSINEUP-GFP RNA relative to canonical
SINEUP-GFP, as expected from its reduced size. Despite elevated
RNA quantities, no impact was observed on GFPmRNA, proving
that miniSINEUP retains the very same post-transcriptional
mechanism of its full-length counterpart.
SINEUPs can be Targeted to Endogenous
mRNAs of Interest
The use of SINEUPs as a versatile tool to increase protein
synthesis is strictly dependent on their ability to act on
endogenous, cellular mRNAs transcribed from a genomic locus
that does not present a natural SINEUP antisense gene.
To prove this crucial point we designed synthetic SINEUPs
targeted to endogenous DJ-1 mRNA, a gene involved in recessive
familial Parkinson’s Disease (PD). We generated two SINEUP-
DJ-1 constructs with two different BD elements: −40/+32
(long, L), from −40 nucleotides (in annotated 5′ untranslated
region) before DJ-1 translation start site to +32 bases in the
coding sequence, as well as −40/+4 (short, S), ending at the
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FIGURE 4 | Short SINEUPs are active. (A) Domain organization
of miniSINEUP-GFP. Binding (gray) and effector (invB2, red)
domains are indicated. (B) HEK 293T/17 cells were transfected
with pEGFP-C2 and miniSINEUP-GFP (+miniSINEUP). SINEUP-GFP
was included as positive control (+SINEUP). Control cells received
pEGFP-C2 and pcDNA3.1(-) empty plasmid (-SINEUP). Total
proteins (left) and RNA (right) were extracted and tested for
GFP expression and GFP and SINEUP RNA quantities,
respectively. Data are representative of three independent
experiments and indicate mean ± standard deviation.
first nucleotide at 3′ of ATG (Figure 5A). Together with HEK
293T/17, we also carried out experiments in three human
neuronal cell lines [SH-SY5Y, BE(2)-M17 and SK-N-SH cells] as
representative of those frequently used as in vitro system to study
the function of PD-associated genes. Cells transfected with an
empty vector were used as control (-SINEUP).
As shown in Figure 5B, SINEUP activity on endogenous DJ-
1 ranged from 1.7 to 2 fold with no changes in endogenous
DJ-1 mRNA levels. SINEUP-DJ-1 activity was confirmed in all
three human neuronal cell lines, proving the versatility of the
technology (Figures 5C–E). Interestingly, the highest induction
of DJ-1 protein levels was measured in SK-N-SH cells (3 fold).
In summary synthetic SINEUPs can be designed to mRNAs
of interest that do not present a natural SINEUP in their
genomic locus opening up the scalable use of SINEUPs to
target endogenous protein coding transcripts of mammalian
cells.
Discussion
To our knowledge SINEUPs are the only tool available so far that
uses lncRNAs to enhance translation of target proteins. Their
modular structure allows synthetic design of an overlapping
region (BD) to target proteins of interest, without changing the
overall structure of the original lncRNA. Indeed, by extracting
solely the target-selecting BD and the ED from the original
lncRNA, SINEUPs can be resized tominiSINEUPs retaining their
activity.
Over competing technologies, SINEUPs have two major
advantages: (1) they modulate translation of target mRNAs
without introducing stable genomic changes into target cells;
(2) their induction of selected protein is typically in a more
physiological range (2-fold) than most conventional gene
replacement strategies. These features render SINEUPs (and
miniSINEUPs) a potentially interesting tool for a number
of applications. First, SINEUPs may be used as reagents for
molecular biology. As siRNAs have become an invaluable
instrument to inhibit gene expression, many cases exist in
which increasing the amount of a specific protein is required.
SINEUPs may be designed to a single gene of interest or
to a tag that is common to several targets and achieve
translation enhancement, thus formally becoming the opposite
counterpart of siRNAs. This is especially relevant in the
nervous system where regulation of translation has an enormous
impact on synaptic plasticity and memory formation. The
synthesis of specific proteins requires a fine tuned control at
single synapse and spines involving the translation of selective
subtypes of mRNAs. The special challenges posed by the
anatomo-functional organization of the brain require cellular
machinery for controlling mRNAs localization according to
the morphology and connectivity of single neuronal cell types.
This is achieved at least in part by the use of different
TSSs leading to the synthesis of mRNA isoforms with specific
5′UTR containing information for subcellular localization and
translation (Baj et al., 2011). SINEUPs can thus induce
translation from the mRNA isoform expressed in a defined
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FIGURE 5 | SINEUP is active on endogenous mRNA. (A) Scheme of
SINEUP-DJ-1. Two different SINEUPs were designed to target the −40/+32
(L) and −40/+4 (S) regions around the ATG of human DJ-1 gene. Activity of
SINEUP-DJ-1 was tested in non-neuronal HEK 293T/17 (B), and in neuronal
SH-SY5Y (C), BE(2)-M17 (D) and SK-N-SH (E) cells. Controls were
transfected with empty pcDNA3. Protein (top) and RNA (bottom) levels were
analyzed by Western blot with anti-DJ-1 antibody and by qRT-PCR with
SINEUP (white) and target-specific (gray) primers, respectively. SINEUP
activity was calculated as increase in protein levels relative to empty control
samples (fold changes are shown). In all conditions, DJ-1 mRNA quantities
were stable (p > 0.05). Data indicate mean ± standard deviation and are
representative of three independent experiments.
cellular compartment of a selected neuronal cell type increasing
specificity.
Here we show that a synthetic SINEUP against the
endogenous mRNA for DJ-1, a gene involved in familial PD, is
able to increase its protein synthesis. This is important since,
to our knowledge, the mammalian genomic DJ-1 locus does
not present a natural SINEUP. This experiment thus proves
SINEUPs can potentially act on protein coding transcripts of
mammalian cells whether or not they are under an endogenous
SINEUP-mediated translational control.
Second, considering their effect on translation, SINEUPs
may find applications in protein manufacturing. More than
130 therapeutic proteins are currently in use and many more
are under development, including antibodies (Leader et al.,
2008). Most production strategies have concentrated efforts in
optimizing culture conditions and transcription of recombinant
genes leaving room for improvement at post-transcriptional
level. Recently, large-scale manufacturing platforms have been
developed using transiently transfected cells, mainly CHO and
HEK293 (Bandaranayake and Almo, 2014). The data presented
here and elsewhere (Cotella et al., submitted) support the
feasibility of SINEUPs and their potential to be integrated in
existing platforms.
Several aspects regulating SINEUP efficacy with selected
targets have still to be elucidated. Here we found that, despite
identical sequence in the overlapping region, SINEUP-FLAG
failed to up-regulate FLAG-TTRAP, whilst being the most
effective with FLAG-TRAF6. Furthermore, the very same BD
directed to a singlemRNA species can increase protein levels with
different efficacies according to the host cellular type. Finally,
BD of different lengths can act unlike. In this context the role
of the secondary structure of the target mRNAs around AUG
remains unclear, although different levels of protein increase may
be also accounted by turnover rates specific for each protein
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or cellular context. While testing synthetic SINEUPs against a
large repertory of endogenous mRNAs, we have found that a
major cause of apparent lack of activity is due to the wrongful
assumption that cells express the Refseq mRNA isoform of
the gene. As shown by genome-wide analysis of TSS usage
in mammalian cells, the complexity of alternative 5′ ends of
mRNAs is staggering. Therefore, when available, we routinely
interrogate the FANTOM5 dataset of CAGE libraries (Forrest
et al., 2014) of the very same cells used in the experiments taking
advantage of the online tool Zenbu (http://fantom.gsc.riken.jp/
5/) to identify the correct AUG-surrounding region of the mRNA
of interest. Importantly, we observed that high number of cell
passages negatively influence SINEUP activity (data not shown).
Global CAP-dependent translation is maintained through mTOR
activity (Laplante and Sabatini, 2012) and is reduced in the
majority of stress conditions (Holcik and Sonenberg, 2005;
Sonenberg and Hinnebusch, 2009). We have previously showed
that inhibition of mTOR with rapamycin induced an increase
in UchL1 protein level dependent on the activity of the natural
SINEUP AS Uchl1 (Carrieri et al., 2012). This occurs by
triggering shuttling of AS Uchl1 RNA from the nucleus to the
cytoplasm and the consequential increased association of Uchl1
mRNA to heavy polysomes for efficient translation. Here we
showed that rapamycin and other stressors do not influence
the amount of protein increase triggered by synthetic SINEUPs.
We may hypothesize that by overexpression we saturate the
cytoplasmic content of SINEUP RNA and/or the quantity of
target mRNAs that can be associated to heavy polysomes. Further
dissection of the cellular pathways that control SINEUP function
and identification of SINEUP-binding proteins will provide
fundamental insights to improve experimental design and answer
these fundamental biological questions.
Finally, lncRNAs represent a new frontier in drug-
development. The field of RNA therapeutics has emerged
for its great potentials and is set to increase the number of
targets beyond initial expectations (Kole et al., 2012). RNA-based
drugs have been developed in the past two decades often
relying on short non-coding molecules, ASOs or siRNAs, to
degrade mRNA or miRNAs of interest. Most recently, lncRNAs
appear as therapeutic targets of ASO technology (Modarresi
et al., 2012), although the field is still at an early phase. The
use of lncRNAs as tools to modulate gene expression is vastly
unexplored. This suffers from the limited knowledge of lncRNAs’
structure/function relationship and from major obstacles in
delivering long RNA molecules. In this context, miniaturization
of lncRNAs represents a prerequisite toward applicability in
therapeutics. Here we demonstrate that SINEUPs’ modular
architecture can be employed to construct a miniSINEUP that
maintains full-length activity with a length within the small RNA
range. Knowing the ED tridimensional structure may provide
further insights to help SINEUPs design and optimize activity
with minimal length requirements.
In current medical practice there are several unmet
therapeutic needs for increasing protein levels in vivo. Among
them, haploinsufficiency is a condition that arises when the
normal phenotype requires the protein product of both alleles,
and reduction to 50% or less of gene function results in an
abnormal phenotype. This is the cause of a wide spectrum
of diseases including ataxias and intellectual and cognitive
disabilities. An efficient SINEUP activity specific for the gene of
interest would be in principle curative. Furthermore, in many
complex and metabolic diseases the increase of pro-survival
factors and dysregulated enzymes may impact the well being of
patients. As an example, augmented production of neurotrophic
factors has been proposed as therapeutic treatments for the
majority of neurodegenerative diseases. Therefore SINEUP
molecules specific for the transcripts selectively expressed
at the site of injury may potentially slow or stop disease
progression. Furthermore, it may avoid the unwanted side effects
of unregulated expression in the brain that have halted many
clinical trials in the past. Our ability to increase endogenous
levels of the PD-associated DJ-1 protein represents the first
formal prove that synthetic SINEUPs may be a new class of
nucleic acid-based drugs.
We are conscious that any potential application of SINEUPs
in therapy will strictly depend on their efficient delivery. To
this purpose we are currently exploring the preservation of
their activity with different delivery systems and chemical
modifications.
In summary, here we show first evidences that synthetic
SINEUPs may represent a scalable platform for manipulating
gene expression of single mRNA species within their
physiological range in an array of cell lines.
SINEUPs may thus become a new tool for laboratory
experiments, for protein manufacturing and for potential
therapeutic intervention in vivo.
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Supplementary Figure 1 | Treatment with stressful stimuli does not
increase SINEUP activity in transfected cells. HEK 293T/17 cells were
transfected with pEGFP in combination with SINEUP-GFP (+SINEUP) or control
plasmid (-SINEUP). After transfection, cells were treated with rapamycin or
doxorubicin as indicated. Lysates were probed anti-GFP antibody. β-actin was
used as loading control. Fold-induction was calculated on Western blot images
normalized to β-actin and relative to empty control samples.
Supplementary Figure 2 | SINEUP RNA is detected in the cytoplasm of
transfected cells. HEK 293T/17 cells were transfected with pEGFP in
combination with SINEUP-GFP (+SINEUP). RNA was purified from separated
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nuclear and cytoplasmic fractions. RNA was reverse transcribed and probed for
SINEUP RNA and GFP mRNA, as indicated. Purity of nuclear and cytoplasmic
fractions was monitored by qRT-PCR on precursor rRNA. Data were normalized to
the level of GAPDH in each fraction and analyzed with the 11 Ct method. RNA
levels in the cytoplasm were set to 1. Data indicate mean ± standard deviation
and are calculated on 3 independent replicas.
Supplementary Figure 3 | SINEUP-increased targets can be detected with
target-specific antibodies. HEK 293T/17 cells were transfected
with pcDNA3-2XFLAG-TRAF6 in combination with SINEUP-FLAG (+SINEUP) or
control plasmid (-SINEUP). Lysates were probed anti-TRAF6 antibody.
Supplementary Figure 4 | SINEUP-FLAG does not increase FLAG-TTRAP
protein levels. HEK 293T/17 cells were transfected with
pcDNA3-2XFLAG-TTRAP in combination with SINEUP-FLAG (+SINEUP) or control
plasmid (-SINEUP). Lysates were probed anti-FLAG antibody. SINEUP RNA and
TTRAP mRNA were quantified by qRT-PCR with specific primers. Data indicate
average ± stdev and are representative of n = 3 independent experiments.
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